|
|
Last Modified: 7/12/2007  First Published: 12/18/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 to 80
|
|
|
|
Other
|
|
|
|
CRUK-HILO-BRD/05/83 ISRCTN56078540, EU-20665, CTA-20363/0217/001/0001, EUDRACT-2005-003687-37, NCT00415233
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Approved-not yet active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
Estimabl CSET 1216, NCT00435851
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
16 and over
|
|
|
|
NIDDK
|
|
|
|
060025 06-DK-0025, NCT00251316
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
04-116 NCT00673010
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Biomarker/Laboratory analysis, Diagnostic, Natural history/Epidemiology
|
|
|
|
Active
|
|
|
|
Any age
|
|
|
|
NIDDK
|
|
|
|
770096 77-DK-0096, NCT00001160
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Diagnostic, Supportive care
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
CRC 03-52-R1 NCT00223158
|
|
|
|
|
|
|
|
First Published: 12/21/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Diagnostic, Treatment
|
|
|
|
Active
|
|
|
|
18 to 100
|
|
|
|
NCI
|
|
|
|
JHOC-NA_00002264 NCT00416949
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Diagnostic
|
|
|
|
Active
|
|
|
|
Over 18
|
|
|
|
Other
|
|
|
|
CCR3047 NCT00749697
|
|
|
|